Defining treatment-resistant depression: A comprehensive review of the literature

Annals of Clinical Psychiatry

Volumn 26, Issue 3, 2014, Pages 222-232

  Trevino, Kenneth ^a   McClintock, Shawn M ^a,b   Fischer, Noelle McDonald ^a   Vora, Ankita ^a   Husain, Mustafa M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b and Psychology and Neuroscience   (United States)

Author keywords

Drug resistance; Major depressive disorder; Risk factors; Staging models; Treatment failure; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PHENELZINE; PROTRIPTYLINE; REBOXETINE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

CLINICAL ASSESSMENT TOOL; CLINICAL RESEARCH; COMORBIDITY; DATA BASE; DISEASE DURATION; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; HEALTH CARE ACCESS; HUMAN; MAJOR DEPRESSION; MASSACHUSETTS GENERAL HOSPITAL STAGING METHOD; MEDICAL RECORD REVIEW; MEDLINE; MENTAL HEALTH SERVICE; NERVE STIMULATION; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; REVIEW; RISK FACTOR; SOCIAL PSYCHOLOGY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; CLASSIFICATION; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC ERROR; SEVERITY OF ILLNESS INDEX;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC ERRORS; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 84922213391     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Fava M. Diagnosis and definition of treatmentresistant depression. Biol Psychiatry. 2003;53:649-659.
2. Berman RM, Narasimhan M, Charney DS. Treatmentrefractory depression: definitions and characteristics. Depress Anxiety. 1997;5:154-164.
3. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry. 2003;53:640-648.
4. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17.
5. Sharan P, Saxena S. Treatment-resistant depression: clinical significance, concept and management. Natl Med J India. 1998;11:69-79.
6. Souery D, Amsterdam J, De Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83-91.
7. Berlim M T, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007;52:46-54.
8. Souery D, Papakostas GI, Trivedi MH. Treatmentresistant depression. J Clin Psychiatry. 2006;67(suppl 6):16-22.
9. Malhi GS, Parker GB, Crawford J, et al. Treatmentresistant depression: resistant to definition? Acta Psychiatr Scand. 2005;112:302-309.
10. Nelsen MR, Dunner DL. Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res. 1995;29:43-50.
11. Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry. 1991;148:695-704.
12. Keller MB, Shapiro RW, Lavori PW, et al. Relapse in major depressive disorder: analysis with the life table. Arch Gen Psychiatry. 1982;39:911-915.
13. Paykel ES. Historical overview of outcome of depression. Br J Psychiatry Suppl. 1994;165(suppl 26):6-8.
14. Souery D, Van Der Auwera K. The multiple facets of treatment-resistant depression. CNS Spectr. 2004;9:803-807.
15. O'Reardon JP, Amsterdam JD. Treatment-resistant depression: progress and limitations. Psychiatric Annals. 1998;28:633-640.
16. ∗D report. Psychol Med. 2010;40:41-50.
17. Greden JF. The burden of disease for treatmentresistant depression. J Clin Psychiatry. 2001;62(suppl 16):26-31.
18. Petersen TJ, Papakostas GI, Mahal Y, et al. Psychosocial functioning in patients with treatment resistant depression. Eur Psychiatry. 2004;19:196-201.
19. Rost K, Zhang M, Fortney J, et al. Expenditures for the treatment of major depression. Am J Psychiatry. 1998;155:883-888.
20. Ros S, Agüera L, De La Gándara J, et al. Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand. 2005;112:14-24, 36.
21. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol. 1994;9(suppl 2):5-10.
22. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65:341-347.
23. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-971.
24. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(suppl 8):5-12.
25. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333-340.
26. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):18-25.
27. De Vreede IM, Burger H, Van Vliet IM. Prediction of response to ECT with routinely collected data in major depression. J Affect Disord. 2005;86:323-327.
28. Blom MB, Spinhoven P, Hoffman T, et al. Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. J Affect Disord. 2007;104:119-126.
29. Rubenstein LV, Rayburn NR, Keeler EB, et al. Predicting outcomes of primary care patients with major depression: development of a depression prognosis index. Psychiatr Serv. 2007;58:1049-1056.
30. Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry. 2008;20:209-218.
31. Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry. 2002;36:384-391.
32. Mynors-Wallis L, Gath D. Predictors of treatment outcome for major depression in primary care. Psychol Med. 1997;27:731-736.
33. McGrath PJ, Stewart JW, Quitkin FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163:1542-1548.
34. Vieta E, Colom F. Therapeutic options in treatmentresistant depression. Ann Med. 2011;43:512-530.
35. Janicak PG, Dowd SM. Treatment-resistant depression: an update on diagnosis and management. Psychopharm Review. 2009;44:41-48.
36. Kennedy SH. Treating each and every depressed patient. J Psychopharmacol. 2008;22(suppl 7):19-23.
37. Thase ME. The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Psychiatr Clin North Am. 1996;19:287-309.
38. Fava M, Uebelacker LA, Alpert JE, et al. Major depressive subtypes and treatment response. Biol Psychiatry. 1997;42:568-576.
39. ∗D report. Am J Psychiatry. 2008;165:342-351.
40. Kessler RC, McGonagle KA, Zhao S P, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
41. Joffe RT, Bagby R, Levitt A. Anxious and nonanxious depression. Am J Psychiatry. 1993;150:1257-1258.
42. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry. 2006;51:823-835.
43. Worthington JJ, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996;37:518-522.
44. Castaneda R, Sussman N, Westreich L, et al. A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. J Clin Psychiatry. 1996;57:207-212.
45. Sonawalla SB, Papakostas GI, Petersen TJ, et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics. 2002;43:310-316.
46. Bird D, Haddad PM, Dursun SM. An overview of the definition and management of treatment-resistant depression. Bulletin of Clinical Psychopharmacology. 2002;12:92-101.
47. Pohle K, Domschke K, Roehrs T, et al. Medical comorbidity affects antidepressant treatment response in patients with melancholic depression. Psychother Psychosom. 2009;78:359-363.
48. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(suppl 8):17-25.
49. Mulsant BH, Pollock BG. Treatment-resistant depression in late life. J Geriatr Psychiatry Neurol. 1998;11:186-193.
50. Flint AJ. Treatment-resistant depression in late life. CNS Spectr. 2002;7:733-738.
51. Dyck MJ. Treatment-resistant depression: a critique of current approaches. Aust N Z J Psychiatry. 1994;28:34-41.
52. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51:39-47; discussion 48-50.
53. Berlim M T, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17:696-707.
54. Rush AJ, Thase ME, Dubé S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743-753.
55. Carvalho AF, Machado JR, Cavalcante JL. Augmentation strategies for treatment-resstant depression. Curr Opin Psychiatry. 2009;22:7-12.
56. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-29.
57. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25:336-341.
58. Ananth J. Treatment-resistant depression. Psychother Psychosom. 1998;67:61-70.
59. Fekadu A, Wooderson SC, Donaldson C, et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70:177-184.
60. Katon W, Lin E, Von Korff M, et al. The predictors of persistence of depression in primary care. J Affect Disord. 1994;31:81-90.
61. Fekadu A, Wooderson SC, Markopoulou K, et al. The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. J Clin Psychiatry. 2009;70:952-957.
62. O'Reardon J P, Brunswick DJ, Amsterdam JD. Treatment-resistant depression in the age of serotonin: evolving strategies. Curr Opin Psychiatry. 2000;13:93-98.
63. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines. 10th ed. London, United Kingdom: Informa Healthcare; 2009.
64. Rush AJ, Kraemer HC, Sackeim HA, et al; ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31:1841-1853.
65. Nierenberg AA, De Cecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):5-9.
66. Fekadu A, Wooderson SC, Markopoulo K, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116:4-11.
67. Carvalho AF, Cavalcante JL, Castelo MS, et al. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther. 2007;32:415-428.